Mendelsohn Aaron
Known title: DirectorCIK: 0001625195
Mendelsohn Aaron's purchase track record
Mendelsohn Aaron has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/29/2025 | VANI | $25K | -25.0% | -3.2% | +7.7% |
| 6/9/2023 | VANI | $13K | -24.7% | -26.6% | +7.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VANI | ▲ Buy | Open Market | 20,000 | $25K | 12/29/2025 | View on chart |
| VANI | ▼ Sell | Gift | 20,000 | $0 | 7/8/2024 | View on chart |
| VANI | ▲ Buy | Open Market | 10,000 | $13K | 6/9/2023 | View on chart |
| VANI | ▼ Sell | Other | 178,170 | $0 | 8/30/2022 | View on chart |
| VANI | ▼ Sell | Other | 150,930 | $0 | 8/30/2022 | View on chart |
| VANI | ▼ Sell | Other | 747,387 | $0 | 8/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Vivani Medical to Appear at Upcoming Investor Conferences
Vivani Medical announced that it will take part in several upcoming investor conferences. The appearances give the company a platform to discuss its pipeline and growth plans with potential investors. The stock is currently trading near its $1.13 support level, which has been tested multiple times, and remains within its 52‑week range of $0.92 to $1.92.
Vivani Medical to Appear at Upcoming Investor Conferences. Vivani Medical announced that it will take part in several upcoming investor conferences. The appearances give the company a platform to discuss its pipeline and growth plans with potential investors. The stock is currently trading near its $1.13 support level, which has been tested multiple times, and remains within its 52‑week range of $0.92 to $1.92.